^
    11h
    MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov)
    P3, N=463, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2027 --> Mar 2028
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole
    11h
    Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=72, Completed, Indiana University | Active, not recruiting --> Completed
    Trial completion
    11h
    A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1/2 trial
    |
    fulvestrant • letrozole
    12h
    Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence (clinicaltrials.gov)
    P=N/A, N=305, Completed, Thomas Jefferson University | Active, not recruiting --> Completed
    Trial completion
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive
    13h
    Nutrition Awareness Among Women With Non-Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, UNC Lineberger Comprehensive Cancer Center
    New trial
    13h
    Modified Title Project 4: Effect of Meal Timing During Cancer Treatment in Alaska Native Patients (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    13h
    PRELUDE: A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, National and Kapodistrian University of Athens
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    EndoPredict®
    14h
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (clinicaltrials.gov)
    P1, N=136, Recruiting, Genentech, Inc. | Trial completion date: Jul 2029 --> Apr 2030 | Trial primary completion date: Jul 2029 --> Apr 2030
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    giredestrant (RG6171) • omeprazole
    14h
    Improving Care for Rural Patients With Solid Tumors (clinicaltrials.gov)
    P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    15h
    An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Shanghai SciBrunch Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    |
    HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation
    15h
    CAFÉ: CTNNA1 Familial Expansion Study (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    CTNNA1 (Catenin Alpha 1)
    16h
    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (clinicaltrials.gov)
    P3, N=1156, Suspended, Alliance for Clinical Trials in Oncology | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • anastrozole • exemestane